In a huge setback a study has found that the Simvastatin-Ezetimibe reduces risk of coronary artery disease (CAD), but does not slow its progression.
The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study was designed to examine the effects of lowering low-density lipoprotein (LDL) cholesterol in patients with aortic stenosis and involved 1,873 patients with mild to moderate aortic stenosis
AdvertisementAll patients were assigned to randomly receive simvastatin 40 mg QD and ezetimibe 10 mg QD or equivalent dose of placebo.
The combination therapy was found to lower LDL or bad cholesterol and thus reduce risk of CAD, but it was not able to slow down the progression of the disease.
You May Also Like